Core Viewpoint - The digital subtraction angiography (DSA) system market is projected to reach $7.974 billion by 2031, with a compound annual growth rate (CAGR) of 7.18% in the coming years [1][4]. Market Overview - Major manufacturers of DSA systems globally include Philips, Siemens Healthineers, and Canon, with the top five companies holding approximately 92.90% of the market share [4]. - The primary product type is the floor-mounted C-arm system, which accounts for about 51.50% of the market [5]. - Cardiovascular diseases represent the largest demand source, capturing around 67.60% of the market [10]. Key Drivers - **Aging Population and Disease Burden**: The acceleration of aging in China and the rising incidence of cardiovascular diseases are driving the demand for DSA in interventional surgeries [14]. - **Policy Support**: The Chinese government is encouraging domestic production of high-end medical equipment through policies like the "Healthy China 2030" plan, which includes funding and tax incentives [14]. - **Technological Integration and Upgrades**: The integration of AI and 3D reconstruction technologies is enhancing diagnostic efficiency and promoting the development of DSA towards precision and minimally invasive procedures [14]. Challenges - **Dependence on Core Components**: High-end DSA equipment relies on advanced components, and while domestic companies have made progress, they still lag behind international giants in key technologies [16]. - **Patent Barriers**: Domestic companies face potential patent infringement issues during R&D, which can hinder innovation [16]. - **Service and Maintenance Costs**: High maintenance costs and insufficient service network coverage for domestic companies compared to international brands pose challenges [17]. Industry Opportunities - **Government Initiatives**: The National Health Commission's guidance on promoting domestic high-end medical equipment development is expected to support local companies [18]. - **Market Expansion in Rural Areas**: The "Thousand County Project" aims for 90% of county-level hospitals to be equipped with DSA devices by 2027, with financial support covering 30%-40% of procurement costs [18]. - **Regulatory Support for Innovation**: The introduction of expedited approval processes for DSA devices with integrated AI functionalities is likely to enhance market entry for innovative products [18].